Americans for Safe Access published a guide Tuesday to help medical cannabis patients understand their rights under the Drug Enforcement Administration's proposed move of marijuana from Schedule I to Schedule III.
The guide, titled "Medical Cannabis Patients: Claim Your Federal Protections & Privileges," explains how the change would affect patient access, employment protections and legal safeguards for medical users and their caregivers.
ASA has advocated for medical cannabis patients since 2002. It put the guide together as the DEA works through the final stages of rescheduling. The agency published its proposed rule in May 2024 and drew more than 40,000 public comments.
What changes for patients
Schedule III, the category that includes ketamine and anabolic steroids, would not legalize medical cannabis at the federal level. It would give patients protections and privileges they have not had under Schedule I.
Medical cannabis would stay a controlled substance requiring a prescription from a licensed physician. But Schedule III status allows for legitimate medical use, a designation that could affect research funding and insurance coverage discussions.
The guide takes up practical questions patients face, such as whether an employer can still fire a worker for medical cannabis use. It also covers VA healthcare for veterans and how rescheduling affects gun ownership rights for medical patients.
The research gap
Rescheduling could speed up clinical research that Schedule I restrictions have held back. Federal barriers have limited large-scale studies of cannabis efficacy and safety.
Under current law, researchers need special DEA licenses and can only get cannabis from a single federal facility. Schedule III classification would ease those restrictions and could lead to larger clinical trials.
Dr. Peter Grinspoon, a physician and cannabis researcher at Massachusetts General Hospital, has said the lack of federal research leaves a knowledge gap. Doctors prescribe medical cannabis based largely on patient reports and limited state-level data, not the gold-standard randomized controlled trials used for conventional medications.
State programs stay in place
Federal rescheduling would not override state medical cannabis programs, which run under their own rules. Thirty-eight states plus Washington, D.C., have legalized medical cannabis in some form.
Patients in those states would keep getting medicine through existing dispensary systems. State-issued medical cannabis cards would remain the primary form of patient identification.
The federal change could still shape how states structure their programs. Some advocates expect Schedule III status to nudge holdout states toward establishing medical programs, and existing programs could gain legitimacy in the eyes of healthcare institutions.
What's next
The DEA has not announced a timeline for finalizing the rule. The agency must review the public comments and could modify the proposal before issuing a final version.
ASA's guide is available free on the organization's website. The group plans to update it as regulations change and new protections take effect.
For now, medical cannabis patients remain in a legal gray area at the federal level. The guide lays out what protections exist today and what would change once rescheduling becomes official.
This article is based on original reporting by ganjapreneur.com.
